Relevant Degree Programs
Affiliations to Research Centres, Institutes & Clusters
Graduate Student Supervision
Doctoral Student Supervision (Jan 2008 - Nov 2019)
The full abstract for this thesis is available in the body of the thesis, and will be available when the embargo expires.
Previous studies have revealed that perturbations in myelopoiesis can lead to the emergence of immature cells, which can facilitate tumorigenesis and metastasis. Our studies showed that mammary tumours led to a myeloproliferative-like disease, characterized by anemia, leukocytosis, expansion of immature myeloid cells, and defects in the hematopoietic stem and progenitor cell (HSPC) compartment in tumour-bearing mice. Furthermore, mammary tumours impaired DC development resulting in the accumulation of DC progenitors and the emergence of immunosuppressive DCs with impaired ability to activate NK and T cells. Mammary tumour-bearing mice exhibited a shift in hematopoiesis from the bone marrow to the spleen, with large numbers of primitive and committed progenitors accumulating in the spleen. Mammary tumour development was also associated with epigenetic modifications that facilitated the expression of key hematopoiesis and leukemia regulatory genes, such as Hoxa9, a gene that critically controls HSPC differentiation. Using in vitro assays, we identified mammary tumour derived G-CSF as the factor mediating the dysregulation of the HSPC compartment and suppressing DC development. DCs are critical for the priming/activation of NK cells and cytotoxic T lymphocytes, which together are critical components of the anti-tumour immune response. Therefore, proper regulation of signaling thresholds is critical for DC activation and function. Lyn tyrosine kinase is important in regulating signaling thresholds in immune cells, including DCs, and Lyn gain-of-function (Lynup/up) mice show increased sensitivity to PAMPs (i.e. LPS) characterized by high levels of proinflammatory cytokines and increased susceptibility to endotoxin-mediated death. Our studies demonstrated that DCs were necessary for the enhanced LPS-induced inflammation in Lynup/up mice, by priming excessive IFN-γ production by NK cells. As such, we hypothesized that enhanced Lyn activity, and the associated changes in DC development and activation will evoke improved anti-tumour immune responses and preliminary data from our lab demonstrates that Lynup/up mice develop smaller mammary tumours than wild type mice. Taken together, our results suggest that targeting mammary tumour derived G-CSF may reverse mammary tumour-induced anemia, leukocytosis, and DC defects, conversely enhancing DC function by increasing Lyn activity may result in in a more robust anti-tumour immune response, leading to increased survival of breast cancer patients.
Master's Student Supervision (2010 - 2018)
Tumours are often associated with defects in hematopoiesis and DC function. Leukocytosis, anemia, development of immunosuppressive cells such as MDSCs and tolerogenic DCs are all part of tumour development. In breast cancer, although these hematopoietic and DC defects may serve as prognostic indicators, little is known about their origin. Our studies show that mammary tumours affect the hematopoietic system leading to myeloproliferative-like disease characterized by neutrophilia, anemia, and defects in the HSPC compartment. These defects were associated with changes in global epigenetic regulation, and specifically in the upregulation and histone methylation status of Hoxa genes, most notably Hoxa9, a gene that critically controls HSPC differentiation. These changes in gene regulation and HSPC defects were found to be driven by tumour-secreted G-CSF. Additionally, our research shows that the generation of immunosuppressive DCs in mammary tumour bearing mice was associated with impaired DC differentiation, where DCs that develop in the presence of mammary tumours and their factors acquire immunosuppressive features. G-CSF played an important role in the suppression of DC development. Tumour derived factors induced FLT3L and GMCSF DCs to expression Arginase-I, an enzyme known to suppress T cell proliferation and induce tolerance. Our data revealed the expression of Arg1 in these DCs was associated with enabling histone modifications in the Arg1 locus. Targeting of G-CSF may alleviate tumourinduced symptoms of anemia, leukocytosis, and DC defects, resulting in better patient survival and preventing DC immunosuppression.